Analysts Raise ANI Pharmaceuticals’ 2026 EPS to $9.00 as Shares Fall 5%
Analysts raised ANI Pharmaceuticals’ 2026 EPS forecast by 8.7% to $9.00 and its 2027 EPS estimate by 9.2% to $10.10 over the past 60 days. The stock has declined 5% year-to-date while the company posted four consecutive quarterly earnings beats averaging a 22.2% surprise.
1. EPS Estimate Revisions
Over the past 60 days, consensus forecasts for ANI Pharmaceuticals’ 2026 earnings per share have climbed from $8.28 to $9.00, while 2027 EPS expectations rose from $9.25 to $10.10, reflecting growing analyst confidence in the company’s revenue outlook.
2. Stock Performance and Earnings Surprises
Despite these upward estimate revisions, ANI’s shares have slid 5% year-to-date. The company has delivered four straight quarterly earnings beats, with an average surprise of 22.21%, underscoring its ability to exceed analyst projections.